Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Drawing of the earth with representations of locations and interactions © Flickr, Cristhian Alama, Red Mundial

Artemisinin-based combination therapy is the first-line antimalarial treatment for uncomplicated falciparum malaria in most endemic countries but can suppress the bone marrow response and also contribute to haemolysis.

This individual patient data pooled analysis quantifies the underlying haematological response following P. falciparum infection to better understand the comparative benefits and risks of different antimalarial treatments.

The publication 'Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data', involved data from 70,226 patients, from 200 studies conducted between 1991 and 2013, with 72.4% enrolled in Africa, 26.3% in Asia and 1.3% in South America.

The paper determined the main factors associated with haematological fall and recovery following uncomplicated malaria and its treatment. The study highlights patients at greatest risk of severe anaemia who would warrant closer follow up and also whether some treatment regimens offer advantages over others with regard to fast recovery and prevention of anaemia.

WWARN researchers highlighted five main findings:

  • A haemoglobin of <7 g/dL is present in 8.4% of people from Africa, 3.3% of people from Asia-Pacific and 0.1% of people from South America
  • The majority of patients with uncomplicated falciparum malaria have a modest fall in haemoglobin following treatment before subsequently improving with recovery
  • Young children are at a particularly high risk of developing malarial anaemia
  • The risk of anaemia during recovery is exacerbated with a slower parasite clearance
  • In Asia, people treated with an artemisinin-based regimen are at a greater risk of anaemia during recovery compared with those treated with a non-artemisinin-based regimen.

Read the publication 'Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data' on the BMC Medicine website

The full story is available on the WWARN website

Similar stories

Field evaluation of EasyScan GO: a digital malaria microscopy device

Microscopic examination of Giemsa-stained blood films is key to quantifying and detecting malaria parasites but there can be difficulties in ensuring both a high-quality manual reading and inter-reader reliability. The EasyScan GO was developed as a potential solution to this, a microscopy device using machine-learning-based image analysis for automated parasite detection and quantification.

Registration is open for The Global Health Network Conference 2022

To tackle disease we need evidence to be generated through every type of health research study. This conference aims to bring together health research teams, organisations, health-workers, policy makers and practitioners to explore together how health research can be embedded into every healthcare setting. Join us at The Global Health Network Conference 2022 at the University of Cape Town, South Africa, 24 – 25 November 2022

The inside story of Recovery: how the world’s largest COVID-19 trial transformed treatment – and what it could do for other diseases

Two years ago, the Recovery trial transformed the care of COVID patients with its dexamethasone announcement. Within four hours, the steroid was included in NHS treatment recommendations. Almost overnight, treatment of COVID patients around the world changed completely. It has been estimated that dexamethasone may have saved a million lives in the first nine months following the announcement. Recovery is a groundbreaking scientific machine which, from the outset, moved at unprecedented speed. In the first 100 days alone, the trial produced three groundbreaking results that would completely reshape COVID care.

Gail Carson chair of GOARN

Dr Gail Carson from the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) is nominated chair of WHO Global Outbreak Alert & Response Network (GOARN)

RECOVERY trial celebrates two-year anniversary of life-saving dexamethasone result

Two years ago, the RECOVERY trial gave the world its first breakthrough against coronavirus: the discovery that an inexpensive steroid pill, dexamethasone, reduced deaths by up to a third from COVID-1. Within hours, the result was breaking news across the world and hospitals were adopting the drug into the standard care given to all patients with COVID-19. In the nine months following the discovery, dexamethasone saved an estimated one million lives worldwide.

Congratulations to Professor Sir David Warrell, appointed Knight Commander of the Order of St Michael and St George!

David Warrell, MORU founding director, has been appointed by the Queen ‘Knight Commander of the Order of St Michael and St George for services to global Health Research and Clinical Practice’. Please join us in congratulating Sir David on receiving this richly deserved high honour!